Brief mention of a mistaken 'buy' on Invion and Phosphagenics from Criterion of the Australian, in his yearly tip round up:
"Our worst miss on the “buy” side was the hapless Slater & Gordon, although to be fair we also called time on the stock well before the share implosion got serious.
Instead of firing, smoking-cessation house Invion coughed and spluttered.
In hindsight, dud retailer Dick Smith didn’t look such a great yield play when it traded at $2.24 a share in May.
Backing Phosphagenics, a biotech still reeling from the jailing of its chief executive on fraud charges last year, was a case of what drug were we on? "
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)